Fly News Breaks for March 2, 2020
Mar 2, 2020 | 14:44 EDT
Wedbush analyst David Nierengarten raised the firm's price target on Karyopharm to $25 from $19 after the company reported positive topline data from the Phase 3 BOSTON trial of selinexor in patients with second-line plus multiple myeloma. While he anticipated a positive BOSTON readout, the magnitude of the PFS benefit over standard treatment was roughly two months longer than he expected, Nierengarten tells investors. He keeps a Neutral rating on the shares as he believes the price reaction to the BOSTON data takes into account sNDA approval for Xpovio in this setting.
News For KPTI From the Last 2 Days